Memo Therapeutics develops fully human therapeutic antibodies by mining the natural immune responses of elite responders to viral infections and cancer using its proprietary DROPZYLLA® platform. Its lead candidate, potravitug, is a Phase II monoclonal antibody targeting BK polyomavirus in kidney transplant patients, and the company is also pursuing novel oncology antibodies derived from tumor‑infiltrating B‑cell repertoires.
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney transplant recipients are at risk of BK polyomavirus (BKPyV) infection, which can cause nephropathy, loss of kidney function, organ failure, rejection, and death. Currently there is no effective therapeutic option to treat or prevent BKPyV infection in this vulnerable population.
Solution
Memo Therapeutics develops therapeutic antibodies derived from the natural immune responses of elite responders to viral infections and cancer. Using its proprietary DROPZYLLA® platform, the company mines antibody repertoires from tumor‑infiltrating B cells and patients who have mounted exceptionally potent immune responses, enabling the identification of high‑affinity antibodies. Its lead candidate, potravitug, is a monoclonal antibody currently in Phase II trials and represents the most potent anti‑BKPyV antibody tested in humans. In parallel, Memo applies the same technology to discover novel antibodies against oncology targets, both as standalone programs and in partnership collaborations. By leveraging naturally occurring immunity, Memo aims to provide targeted, high‑efficacy treatments for viral infections and cancer where existing therapies are insufficient.
Target Audience
Primary customers are transplant physicians and nephrology centers treating kidney transplant recipients, as well as oncology drug developers seeking novel therapeutic antibodies for cancer indications.
Features
- DROPZYLLA® antibody repertoire copying engine that captures and reproduces the most potent antibodies generated by the body’s immune response
- High‑throughput screening of tumor‑infiltrating B‑cell repertoires from elite cancer patients to uncover novel oncology targets
- Fully human monoclonal antibodies with optimized affinity and specificity for viral antigens such as BKPyV
- Clinical‑grade antibody development pipeline, with potravitug advancing through Phase II in kidney transplant patients
- Capability to develop both single‑agent antibodies and combination strategies in partnership settings